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Abstract 25 
Aim: Poorly conducted economic evaluations have the potential to mislead both 26 
clinicians, leading to inappropriate treatment choices, and payers who must decide on 27 
the reimbursement of treatment costs. This paper reviews the methods used in 28 
economic evaluations in haemophilia and proposes standards for conducting and 29 
reporting such evaluations in the future. 30 
 31 
Methods: A systematic review of economic evaluations in haemophilia published since 32 
2008 was conducted. The reporting and methods of the studies were assessed using 33 
the recently published Consolidated Health Economic Evaluation Reporting Guidelines 34 
(CHEERS) checklist. The key methodological deficiencies in the studies were recorded. 35 
 36 
Results: Twenty-one studies met the inclusion criteria, classified as follows: 37 
prophylaxis vs. treatment on-demand (five studies); use of bypassing therapy (six); 38 
immune tolerance induction (four); and other topics (six). In general, the quality of 39 
reporting was good. However, it was poorest for the CHEERS item of patient 40 
heterogeneity, with most studies lacking discussion of heterogeneity in the patient 41 
population. The main recurring methodological deficiencies were the evaluation of 42 
single episodes of care rather than entire treatment strategies; inadequate control for 43 
confounders when comparing treatment options; the frequent use of expert opinion 44 
to determine drug doses and treatment patterns; lack of consideration of patient 45 
heterogeneity; failure to identify patient subgroups; and the inadequate exploration of 46 
uncertainty in estimates. 47 
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 48 
Conclusions: A set of twelve standards for future reporting and conduct of economic 49 
evaluations within haemophilia is proposed, with the objective of making such 50 
evaluations more relevant and reliable for those making treatment and 51 
reimbursement decisions in the future. 52 
 53 
  54 
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Introduction 55 
Treatment decisions remain the sole responsibility of clinicians, yet increasing 56 
pressures on healthcare resources have a direct impact on healthcare funders and 57 
clinicians. Patients may also be concerned about treatment costs if they face 58 
substantial user charges. Hence, clinicians are increasingly requested to consider the 59 
cost/benefit ratios of different therapies. 60 
 61 
Studies assessing the costs and consequences of healthcare treatments and 62 
programmes are known as economic evaluations [1], and a substantial body of 63 
empirical economic studies now cover all branches of healthcare [2]. For these studies 64 
to be helpful to clinicians and patients, they must be both relevant (i.e. address 65 
appropriate treatment choices) and reliable (i.e. have a sound methodology). 66 
Comprehensive and transparent reporting is particularly important to assess whether a 67 
given study is methodologically sound. 68 
 69 
Several systematic reviews have indicated that economic evaluations in haemophilia 70 
often have substantial methodological deficiencies. In a systematic review of 12 71 
studies on bypassing agents (used to treat haemophilia with inhibitors), the authors 72 
concluded that economic models based on different sources of data produced fairly 73 
similar and robust results, but ideally a systematic approach should be used to identify 74 
the relevant data [3]. In another review of 11 studies of bypassing agents, Hay and 75 
Zhou concluded that crucial assumptions about treatment efficacy and dosing drove 76 
the reported findings. Further, eight of nine company-sponsored studies favoured the 77 
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ĐŽŵƉĂŶǇ ?ƐƉƌŽĚuct; the two existing head-to-head clinical studies did not support 78 
superior efficacy for either product [4]. 79 
 80 
In a review of 11 prophylaxis studies, the authors observed that reported cost-81 
effectiveness ratios for prophylaxis varied greatly [5]. They ranged from dominance 82 
over on-demand treatment (i.e. ƐƵƉĞƌŝŽƌĞĨĨŝĐĂĐǇĂŶĚůŽǁĞƌĐŽƐƚ ?ƚŽŽǀĞƌ ? ?ŵŝůůŝŽŶƉĞƌ83 
additional quality-adjusted life-year (QALY) gained if prophylaxis replaces on-demand 84 
treatment after a bleed [5]. The conclusion was that the studies exhibited considerable 85 
methodological differences and that it would be preferable if analysts adhered to 86 
established conventions when conducting and reporting economic evaluations. Finally, 87 
in a literature review on prophylaxis vs. on-demand treatment, using strict 88 
inclusion/exclusion criteria (only five studies were reviewed), authors concluded that 89 
further economic evaluations are required, reflecting the clinical reality and 90 
consumption of resources in each country [6]. 91 
 92 
Poorly conducted economic evaluations have the potential to mislead clinicians and 93 
lead to inappropriate treatment choices. Recently, the Consolidated Health Economic 94 
Evaluation Reporting Standards (CHEERS) became available [7]. CHEERS, comprising a 95 
24-item checklist focusing on the quality of reporting, was developed using CONSORT 96 
methodology [8] and is endorsed by several health services research journals. The 97 
CHEERS guidelines build on the earlier Drummond et al. checklist [9] used in three of 98 
the four reviews cited above, therefore representing an improved assessment tool. 99 
 100 
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The reporting items in the CHEERS checklist reflect the key methodological features of 101 
economic evaluation (Table 1), including study objectives, patient population, 102 
compared treatment alternatives, relative effectiveness of different treatments, 103 
associated resource consumption and relative treatment costs. The checklist also 104 
covers details of the methodology employed, such as the time horizon considered, 105 
discounting of future costs and benefits, characterization of uncertainty in parameter 106 
estimates and consideration of patient population heterogeneity due, for example, to 107 
different disease severities. Furthermore the checklist distinguishes between economic 108 
evaluations conducted alongside an individual clinical study (e.g. randomized 109 
controlled trial [RCT]) and evaluations conducted using a decision-analytic model, 110 
where data from a variety of sources are synthesized and analysed. 111 
 112 
 113 
[Table 1 about here] 114 
 115 
This paper aims to (i) use CHEERS to assess the quality of reporting in more recent 116 
economic evaluations in haemophilia; (ii) describe common methodological 117 
deficiencies in greater detail; and (iii) propose standards for conducting and reporting 118 
future economic evaluations. It is hoped that the use of these standards will make 119 
economic evaluations more helpful to clinicians when making treatment choices, and 120 
to payers making reimbursement decisions. 121 
 122 
Methods 123 
 7 
 
We conducted a systematic review of economic evaluations in haemophilia, identifying 124 
all studies published since 2008. This covered all studies other than those included in 125 
the early review by Knight et al. [3] and focused on more recent practices in economic 126 
evaluation. Electronic databases (MEDLINE and Embase) were searched on November 127 
25th, 2015. The search terms and PRISMA diagram are shown in Appendix 1 (available 128 
online). All identified hits were captured and duplicates were removed. Titles and 129 
abstracts were screened to determine whether full-text articles should be retrieved 130 
and reviewed for eligibility. Eligibility criteria included disease area (haemophilia, all 131 
types), patient group (human, adults and children), language (English), year of 132 
publication (2008 and later) and document type (journal article). Reasons for excluding 133 
articles were recorded. Conference abstracts were excluded as these provide 134 
insufficient detail to judge the reporting quality of studies.  135 
 136 
Identified studies were assessed by two reviewers (NH and MD) using the CHEERS 137 
checklist. Any differences of opinion were resolved between the two reviewers to 138 
obtain a summary of reporting standards of the included studies.  139 
 140 
 141 
Results 142 
Twenty-one economic evaluations met our inclusion criteria and were grouped under 143 
the following topics: prophylaxis vs. treatment on demand (five studies) [10 ?14]; 144 
bypassing therapy use (six studies) [15 ?20]; immune tolerance induction (four studies) 145 
[21 ?24]; and other topics within haemophilia (six studies) [25 ?30]. Details of the 146 
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CHEERS assessments for the 15 studies discussing the three main topics are given in 147 
Appendix 2 (available online) and described below. The remaining six studies ŽŶ ‘ŽƚŚĞƌ148 
ƚŽƉŝĐƐ ?ǁĞƌĞŶŽƚĂƐƐĞƐƐĞĚďǇ,Z^ďƵƚĂƌĞdiscussed briefly below. 149 
 150 
Quality of reporting 151 
The CHEERS assessment results are summarized in Table 2. Overall, the quality of 152 
reporting was good. The majority of studies (12) used a decision-analytic model and 153 
three were conducted alongside a single clinical study, although none of these were 154 
RCTs. Reporting quality was poorest for patient heterogeneity: few studies discussed 155 
the importance of patient characteristics or defining subgroups. The procedure for 156 
discounting future costs and benefits was inadequately reported in 10/15 studies, 157 
although some were based on a time horizon of <1 year and discounting would 158 
therefore not be relevant. In seven studies with a time horizon of >1 year, the 159 
reporting standard was not met in four. In decision-analytic modelling studies, 160 
characterization of uncertainty is particularly important; although this was done in the 161 
majority of modelling studies, the ranges of the parameter estimates used in the 162 
sensitivity analyses were not always adequately reported and a probabilistic sensitivity 163 
analysis was not always conducted. An example of a study following the correct 164 
approach is that by Earnshaw et al. (2015) [24]. Finally, although the treatments being 165 
compared were almost always reported, the reasons for choosing the comparator 166 
treatment were rarely given. The CHEERS guidelines state that the choice of 167 
comparators should always be justified. 168 
 169 
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[Table 2 about here] 170 
 171 
Based on the reporting of the studies, identified methodological weaknesses are 172 
discussed for the three main groups of studies below. 173 
 174 
Prophylaxis vs. treatment on demand  175 
In the review of economic evaluations of prophylaxis, key reasons identified for result 176 
variability ŝŶĐůƵĚĞĚĚŝĨĨĞƌĞŶƚĚĞĨŝŶŝƚŝŽŶƐŽĨ ‘ƉƌŽƉŚǇůĂǆŝƐ ? ?ĚŝĨĨĞƌĞŶĐĞƐŝŶƚŚĞĐŚŽŝĐĞof 177 
time horizon, estimates of treatment effect, clotting factor unit cost and discount rates 178 
[5]. As four of the five studies [10 ?14] in the current review included the most recent 179 
studies in the Miners review [5], plus one more recent study, many of the same issues 180 
arise. 181 
 182 
Most authors studied primary prophylaxis vs. on-demand treatment, although one 183 
study reported secondary prophylaxis. The quality of reporting varied, but it was clear 184 
that the prophylactic regimen details differed from one another. However, not all 185 
authors specified when prophylaxis was initiated, the duration and frequency of 186 
infusions, or whether there was dose escalation or change in regimen with increasing 187 
patient age. Given that the costs of clotting factor represent a large percentage of total 188 
treatment costs, it is important that the dosage and unit cost are clearly reported. 189 
 190 
For published economic evaluations, the convention is to report the official list prices 191 
of drugs and the average unit cost estimates for other resource items (e.g. cost of a 192 
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hospital episode). These prices have the advantage of being publicly available and 193 
verifiable. However, prices can vary across healthcare institutions in a given 194 
jurisdiction and across healthcare systems within or between countries. Therefore, it is 195 
important that the published study users check whether the prices used apply in their 196 
institution, and that they explore what implications any price differences might have 197 
for the results. It is therefore helpful if analysts report a sensitivity analysis, in which 198 
the values for the key parameters, such as unit costs, are changed in order to assess 199 
their impact on the overall study results.  200 
 201 
In the earlier review, it was noted that the differing time horizons between studies 202 
could have a major impact on study results [5]. As lifetime therapy is needed for 203 
haemophilia, a lifelong time horizon should ideally be used to cover the costs of 204 
treating adults with clotting factor, averted surgical costs and the longer-term benefits 205 
of preventing bleeds. A lack of long-term clinical data is often used to justify shorter 206 
time horizons, since extrapolation of data to the longer time period required would 207 
introduce uncertainty into the estimates. Normally, economic evaluations use long-208 
term observational studies, such as case series and registries [1], to inform this 209 
extrapolation, but this approach is not typically used in the haemophilia literature. 210 
 211 
All of the studies on prophylaxis vs. on-demand treatment discounted future costs and 212 
benefits, as commonly recommended [1]. The discount rates used varied between 213 
studies, often according to local methods guidelines relevant to where the study was 214 
conducted, but were in the range of 3 ?6% per annum. Discounting reduces the 215 
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quantitative importance of costs and benefits occurring in the future, and therefore 216 
also reduces some of the uncertainty introduced by extrapolation. 217 
 218 
As patient quality of life (QoL) would be expected to differ between similar patients 219 
treated with primary prophylaxis vs. on-demand treatment, this is likely to be an 220 
important factor in economic evaluations for haemophilia. Such pure comparisons are 221 
rarely done in trials, and secondary prophylaxis carries with it reasons for initiation 222 
including frequent bleeding, pain and functional impairment that suggest at least 223 
adults on prophylaxis are likely to have worse initial health-related QoL. In economic 224 
evaluations, QoL is normally reflected in the utility value applied to calculate the QALYs 225 
gained. Many of the reviewed studies followed this approach, but most used utility 226 
values from the existing literature, sometimes estimates from a different country. If 227 
the study result is not very sensitive to the utility values used, this may suffice. 228 
However, consideration should be given to collecting utility data in future clinical 229 
studies, using a widely used generic instrument such as EQ-5D. In addition, 230 
consideration should be given to developing algorithms to map from any descriptive 231 
QoL data typically collected in clinical studies in haemophilia, in order to derive QALY 232 
estimates.. 233 
 234 
Although most of the studies were concerned with the treatment of people with 235 
 ‘ƐĞǀĞƌĞ ?ŚĂĞŵŽƉŚŝůŝĂ with or without inhibitors, there was very little discussion of 236 
patient population heterogeneity (e.g. in disease severity), or whether this would 237 
affect treatment effectiveness or cost. Finally, most studies focused on costs borne by 238 
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the healthcare system, probably because concerns about healthcare costs are often 239 
the motivation for conducting such economic evaluations. However, one might expect 240 
that prophylaxis and on-demand treatment have different impacts on the ƉĂƚŝĞŶƚ ?Ɛ241 
family or their activities in school or work. These impacts would be worth exploring 242 
further, especially given the difference in cost between the two regimens. 243 
 244 
Use of bypassing therapy 245 
All six studies reviewed [15 ?20] examined the comparative cost or cost-effectiveness 246 
of the two available bypassing agents, recombinant activated factor VII (rFVIIa) and 247 
plasma-derived activated prothrombin complex concentrate (pd-aPCC). One of the 248 
main weaknesses in these published economic evaluations stems from the lack of 249 
adequate comparative clinical trials. Only two small head-to-head trials have been 250 
conducted, with contradictory results [31, 32]. As a result, the published economic 251 
studies rely mainly on observational data, from either small single-arm studies or 252 
clinical series, with or without attempts to address potential confounders. The 253 
extensive use of single-arm studies is problematic, as is the selective use of data from 254 
small studies, or comparisons of small prospective studies with real world data that 255 
includes combinations of regimens (e.g. on demand with post-haemostatic 256 
prophylaxis) [33]. One approach to overcoming these problems is to assume 257 
equivalent efficacy of the two therapies [17], reducing the economic study to a cost-258 
minimization analysis. However, this approach would be overly simplistic if there were 259 
important differences between the therapies.  260 
 261 
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An alternative approach is to produce a summary estimate of relative clinical effect by 262 
undertaking a meta-analysis, including the single-arm observational studies [34]. A 263 
major issue in summarizing data from such studies is controlling for potential sources 264 
of confounding. Treur et al. attempted this by performing a Bayesian meta-regression 265 
[35].  266 
 267 
In addition, there is uncertainty concerning the equivalence of the doses of the two 268 
therapies, either because of variations in patient weight or the number of infusions of 269 
rFVIIa and pd-aPCC required to achieve haemostasis, the type or severity of bleeds 270 
treated, or differences in the type of data cited (real world compared with clinical 271 
trial). In their sensitivity analysis, Hay and Zhou highlight that pd-aPCC would not be 272 
the lower cost therapy if the rFVIIa dose was assumed to be two infusions per line or 273 
episode of therapy, rather than three (as in their base-case analysis) [17]. 274 
Furthermore, some studies consider the comparative costs of treating a single bleed, 275 
but those considering multiple treatment events have to estimate the probability of 276 
treatment switching or augmentation. Many of the studies use estimates from either 277 
the literature or expert opinion without providing details of the search methods used 278 
or justifying why those particular sources are the most appropriate. This is potentially 279 
problematic given that the results of studies are often very sensitive to these 280 
parameters. 281 
 282 
Ideally, these issues could be resolved by conducting a long-term clinical trial in which 283 
patients are randomized to first-line treatment with one of the bypassing agents, with 284 
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subsequent treatments being determined by physicians as they would in normal 285 
clinical practice. One could then observe a series of treatment decisions over time for 286 
equivalent patients who differ only in the initial random assignment of therapy. 287 
However, RCTs can be difficult to conduct and analyse, although they have formed the 288 
basis for cost-effectiveness assessments in other therapeutic areas [36, 37]. Given the 289 
small percentage of haemophilia patients developing inhibitors, such a trial is unlikely 290 
to be feasible. Therefore, the very small sample sizes available in the inhibitor segment 291 
increase the risk of selection bias when performing evaluations. Transparency thus 292 
becomes especially important when reporting results and stating conclusions.  293 
 294 
If a RCT cannot be conducted, a second-best approach is to establish a registry of 295 
patients who are treated with differing bypassing agents and then analyse the data, 296 
adjusting for known and unknown confounders. The main problems here lie in having 297 
enough data on possible confounders to make the adjustments, through either 298 
multivariable regression or propensity scoring, and in needing an approach to deal 299 
with unknown confounders. The approach favoured in many economic analyses is to 300 
use an instrumental variable (IV) in the regression analysis [38].  An IV is a variable that 301 
does not itself belong in the explanatory equation, but is correlated with ƉĂƚŝĞŶƚƐ ?302 
treatment allocation based on other covariates, but not correlated with treatment 303 
outcome. For example, in an evaluation of diabetes treatment, Prentice et al. used 304 
variation in physician prescribing (i.e. frequency of use of one drug vs. another) as an 305 
IV, since these prescribing variations would influence treatment while being effectively 306 
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random with respect to patient risk and other potential influences on treatment 307 
outcome [39].  308 
 309 
However, many of the registries established in haemophilia are unable to inform 310 
estimates of relative treatment effect, since all the patients enrolled are treated with 311 
the same therapy. Although some good patient registries do exist, such as the one in 312 
the United Kingdom (www.ukhcdo.org), they often have inadequate detail to adjust 313 
for potential confounders or data on treatment patterns to facilitate an accurate 314 
costing of different treatments. The methodological and practical issues in establishing 315 
a registry that facilitates economic evaluations should be investigated. An important 316 
issue in the design of future registries and other clinical studies is the standardization 317 
of definitions for terms such as  ‘ũŽŝŶƚbleeds ? and  ‘target joints ?, to more easily enable 318 
comparisons between studies [40]. Further, it needs to be clear whether the 319 
information captured about administration relates to bleed treatment or is being 320 
administered as post-haemostatic prophylaxis. This becomes more complicated in the 321 
situation of capturing breakthrough bleed treatment during bypassing agent 322 
prophylaxis, where it becomes even less clear when bleed treatment ends and 323 
prophylaxis per se resumes. 324 
 325 
Immune tolerance induction 326 
All four of the reviewed studies considered alternative strategies for treating patients 327 
with inhibitors [21 ?24]. These strategies included prophylaxis or on-demand treatment 328 
with a bypassing agent, low- and high-dose immune tolerance induction (ITI) regimens 329 
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and ITI treatment based on risk assessment. While all the studies modelled treatments 330 
and outcomes over time, the reported time horizon varied between 1 ?1.5 years and a 331 
lifetime, often with no justification given for the time horizons chosen. All studies 332 
recognized patient population heterogeneity ?ŶŽƚŝŶŐƚŚĂƚƉĂƚŝĞŶƚƐĐŽƵůĚďĞ ‘ŚŝŐŚƌŝƐŬ ?333 
Žƌ ‘ůŽǁƌŝƐŬ ? of anamnestic response, but the extent to which patient heterogeneity 334 
could impact the cost-effectiveness of the various strategies was explored to differing 335 
degrees. 336 
 337 
For bypassing therapy, little or no head-to-head clinical data compared the various 338 
treatment strategies particularly during ITI, and some synthesis of data from different 339 
sources was required. The various studies differed in the robustness of their literature 340 
reviews, which were not always systematic. Some of the uncertainties found in the 341 
literature on bypassing agents (e.g. doses required) also carry over into the literature 342 
on ITI. 343 
 344 
One additional feature of this body of literature is the use, in some studies, of QALYs as 345 
the main outcome for the economic evaluation. This is more consistent with the 346 
broader literature on economic evaluation and in keeping with many of the formal 347 
methods guidelines that exist in various jurisdictions. In principle, this approach is 348 
relevant for many of the haemophilia treatment choices, as differences in bleeding 349 
frequency or the care setting are likely to impact patient QoL. However, the literature 350 
on utility values for people with haemophilia is itself quite limited, especially as many 351 
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patients are children or adolescents. The generation of utility values for this patient 352 
population should be considered. 353 
 354 
As observed in the literature on prophylaxis and bypassing therapy, various 355 
uncertainties in economic analyses of ITI exist. Extensive use of sensitivity analyses is 356 
therefore advisable in order to help the users of studies appreciate the impact these 357 
uncertainties have on the relative cost-effectiveness of therapies. Furthermore, 358 
estimates of the success rates of ITI fail to account for reoccurrence of inhibitors. 359 
 360 
Other clinical topics in haemophilia 361 
Six studies evaluating other haemophilia therapeutic options were identified, covering 362 
a wide range of topics: home-based care [28], screening for intracranial haemorrhage 363 
in neonates with haemophilia [29], high vs. standard initial doses of rFVIIa [30], pd-364 
aPCC vs. rFVIIa in haemophilia patients with inhibitors undergoing major orthopaedic 365 
surgeries [26] and major knee surgery with rFVIIa in patients with high-titre inhibitors 366 
[25]. The literature review also identified one other study on bypassing therapy, which 367 
is interesting in that it uses a pre- and post-treatment design, but only examines the 368 
impact of a single bypassing agent in three patients [27]. Because of the diversity of 369 
topics, these six studies were not analysed using the CHEERS checklist, but were 370 
assessed to determine whether they offered any other methodological insights. Three 371 
points merit more discussion. 372 
 373 
 18 
 
First, a study of home-based care utilized a de novo survey of 105 patients to generate 374 
utility estimates of home- and hospital-based care [28]. Potential differences in 375 
convenience offered to patients and their families by different treatments is an 376 
important area [41] that deserves more attention in the published literature. 377 
 378 
Second, in the study of rFVIIa in knee surgery [25], utility values were generated using 379 
the EuroQoL 5-dimension, a generic utility instrument widely used across several 380 
therapeutic areas and favoured by some decision-makers [42]. However, this study 381 
was predominantly about knee surgery, not treatment of haemophilia per se, so the 382 
health state values generated may not have relevance to other economic evaluations 383 
in haemophilia. 384 
 385 
Finally, the study comparing high and standard initial doses of rFVIIa used registries to 386 
collect data on the frequency of bleeds and the resulting treatment patterns [30]. 387 
While statistical adjustments were made for patient characteristics through 388 
multivariate analysis, this was restricted owing to the limited nature of the data 389 
recorded in the registry. 390 
 391 
Future developments in treatments for haemophilia 392 
There are several developments in haemophilia treatment for which no published 393 
economic evaluations were available at the time of this review. Extended half-life 394 
clotting factor products might change the way in which treatment is approached. 395 
Patients may be able to reduce injection frequency while maintaining high trough 396 
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levels to protect against bleeds, particularly in the case of Factor IX. Therefore, the use 397 
of other resources, such as hospital and physician visits, could be reduced. Innovative 398 
molecules like monoclonal antibodies or FVIII mimetics can change the treatment 399 
paradigm with new mechanisms of action and easier methods of administration, such 400 
as subcutaneous injection. If successful, these alternatives may improve the treatment 401 
and lives of haemophilia patients, whereas gene therapy, when feasible, will remove 402 
the risk of bleeding completely. In order to justify the expected higher costs of these 403 
new therapies, the methods of economic evaluation need to be equal to the task of 404 
accurately assessing cost-effectiveness. In addition, expensive new health technologies 405 
(e.g. gene therapy) may require the development of new methods of reimbursement 406 
[43], which will also need to be informed by economic evaluation. 407 
 408 
Discussion 409 
The existing literature on the economic evaluation of haemophilia treatments has 410 
several recurring methodological deficiencies. These include uncertainties about the 411 
relative efficacy of treatments, lack of clarity on the doses required or used in practice 412 
and the analysis of individual treatment episodes rather than whole therapeutic 413 
strategies, with inadequate description and analysis of treatment switches. Therefore, 414 
the results of most published studies are subject to considerable uncertainty and, 415 
without an extensive sensitivity analysis, the results should be treated with caution.  416 
 417 
The first step to improvement is to ensure that studies are reported thoroughly and 418 
systematically, using the CHEERS reporting standard. This is imperative to allow the 419 
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quality of the methods used to be judged and to identify key assumptions that impact 420 
the study results. For this reason, we excluded conference abstracts and posters from 421 
our review, as they do not allow enough space to explain methods thoroughly and 422 
therefore provide an inadequate basis for making treatment choices or reimbursement 423 
decisions. 424 
 425 
In addition, it is necessary to develop some methodological standards for studies in 426 
haemophilia, based on the general methodological principles of economic evaluation 427 
[1]. We propose some aspirational standards in Table 3 that may not always be 428 
attainable. For example, whereas long-term studies are often desirable, they may not 429 
be possible if the treatment of interest has been only recently introduced, or if the 430 
main interest of decision-makers is short-term budgetary impact. 431 
 432 
[Table 3 about here] 433 
 434 
However, the implementation of these standards would improve the quality of the 435 
published literature, enabling a higher level of confidence in the study results and an 436 
understanding of the basis for competing claims. Given the difficulties in conducting 437 
definitive clinical studies, there will always be considerable uncertainties. Therefore, 438 
item #10 of our proposed standards, the characterization of uncertainty, is particularly 439 
important, as is item #12, which advocates discussing the main study limitations and 440 
why the results may differ from those of other published studies investigating the 441 
same treatment strategies. 442 
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 443 
Other items might be particularly important to a physician deciding on the choice of 444 
treatment for a particular patient. These could include item #7, concerning the 445 
assessment of health outcomes in QoL, and item #11, which deals with patient 446 
convenience and preferences and the broader impact the disease and its treatment 447 
has on families. 448 
 449 
Conclusions 450 
The growing literature on the economic evaluation of haemophilia treatments reflects 451 
increasing concerns about rising healthcare costs. Although the quality of reporting in 452 
studies is generally good, several recurring methodological weaknesses exist. Given 453 
that economic evaluations are likely to become more important as new treatments are 454 
developed, there is a need for improved methodological standards. By identifying 455 
examples of poor methodology, and offering suggestions for improvement, it is hoped 456 
that this paper will help to make studies more relevant and reliable for future 457 
treatment and reimbursement decisions. 458 
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 617 
Table 1. CHEERS ĐŚĞĐŬůŝƐƚդitems to include when reporting economic evaluations of health 618 
interventions (reproduced from Husereau et al., 2013 [7]). 619 
Section/item Item 
no. 
Recommendation Reported 
on page 
no./line 
no. 
    
Title and abstract     
Title 1 Identify the study as an economic evaluation, or use more 
specific terms such as  ‘cost-effectiveness analysis ? and 
describe the interventions compared. 
______ 
Abstract 2 Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), 
results (including base-case and uncertainty analyses), and 
conclusions. 
______ 
Introduction    
Background and 
objectives 
3 Provide an explicit statement of the broader context for the 
study. 
______ 
  Present the study question and its relevance for health 
policy or practice decisions. 
______ 
Methods    
Target population 
and subgroups 
4 Describe characteristics of the base-case population and 
subgroups analysed including why they were chosen. 
______ 
Setting and location 5 State relevant aspects of the system(s) in which the 
decision(s) need(s) to be made. 
______ 
Study perspective 6 Describe the perspective of the study and relate this to the ______ 
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costs being evaluated. 
Comparators 7 Describe the interventions or strategies being compared 
and state why they were chosen. 
______ 
Time horizon 8 State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate. 
______ 
Discount rate 9 Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. 
______ 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the type of 
analysis performed. 
______ 
Measurement of 
effectiveness 
11a Single studyʹbased estimates: Describe fully the design 
features of the single effectiveness study and why the 
single study was a sufficient source of clinical effectiveness 
data. 
______ 
 11b Synthesis-based estimates: Describe fully the methods used 
for the identification of included studies and synthesis of 
clinical effectiveness data. 
______ 
Measurement and 
valuation of 
preference-based 
outcomes 
12 If applicable, describe the population and methods used to 
elicit preferences for outcomes. 
______ 
Estimating 
resources and costs 
13a Single studyʹbased economic evaluation: Describe 
approaches used to estimate resource use associated with 
the alternative interventions. Describe primary or 
secondary research methods for valuing each resource item 
in terms of its unit cost. Describe any adjustments made to 
______ 
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approximate to opportunity costs. 
 13b Model-based economic evaluation: Describe approaches 
and data sources used to estimate resource use associated 
with model health states. Describe primary or secondary 
research methods for valuing each resource item in terms 
of its unit cost. Describe any adjustments made to 
approximate to opportunity costs. 
______ 
Currency, price 
date and 
conversion 
14 Report the dates of the estimated resource quantities and 
unit costs. Describe methods for adjusting estimated unit 
costs to the year of reported costs if necessary. Describe 
methods for converting costs into a common currency base 
and the exchange rate. 
______ 
Choice of model 15 Describe and give reasons for the specific type of decision-
analytic model used. Providing a figure to show model 
structure is strongly recommended. 
______ 
Assumptions 16 Describe all structural or other assumptions underpinning 
the decision-analytic model. 
______ 
Analytic methods 17 Describe all analytic methods supporting the evaluation. 
This could include methods for dealing with skewed, 
missing, or censored data; extrapolation methods; methods 
for pooling data; approaches to validate or make 
adjustments (e.g. half-cycle corrections) to a model; and 
methods for handling population heterogeneity and 
uncertainty. 
______ 
Results    
Study parameters 18 Report the values, ranges, references, and if used, 
probability distributions for all parameters. Report reasons 
______ 
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or sources for distributions used to represent uncertainty 
where appropriate. Providing a table to show the input 
values is strongly recommended. 
Incremental costs 
and outcomes 
19 For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, as 
well as mean differences between the comparator groups. 
If applicable, report incremental cost-effectiveness ratios. 
______ 
Characterizing 
uncertainty 
20a Single studyʹbased economic evaluation: Describe the 
effects of sampling uncertainty for estimated incremental 
cost, incremental effectiveness, and incremental cost-
effectiveness, together with the impact of methodological 
assumptions (such as discount rate, study perspective). 
______ 
 20b Model-based economic evaluation: Describe the effects on 
the results of uncertainty for all input parameters, and 
uncertainty related to the structure of the model and 
assumptions. 
______ 
Characterizing 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between 
subgroups of patients with different baseline 
characteristics or other observed variability in effects that 
are not reducible by more information. 
______ 
Discussion    
Study findings, 
limitations, 
generalizability and 
current knowledge 
22 Summarize key study findings and describe how they 
support the conclusions reached. Discuss limitations and 
the generalizability of the findings and how the findings fit 
with current knowledge. 
______ 
Other    
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Source of funding 23 Describe how the study was funded and the role of the 
funder in the identification, design, conduct and reporting 
of the analysis. Describe other nonmonetary sources of 
support. 
______ 
Conflicts of interest 24 Describe any potential for conflict of interest among study 
contributors in accordance with journal policy. In the 
absence of a journal policy, we recommend authors comply 
ǁŝƚŚ/ŶƚĞƌŶĂƚŝŽŶĂůŽŵŵŝƚƚĞĞŽĨDĞĚŝĐĂů:ŽƵƌŶĂůĚŝƚŽƌƐ ?
recommendations. 
______ 
Note. For consistency, the CHEERS statement checklist format is based on the format of the CONSORT 620 
statement checklist. 621 
 622 
  623 
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 624 
Table 2. Reporting standards in the included studies. 625 
CHEERS reporting item Studies meeting the standard 
Yes No Not applicable 
1 Title 14 1  
2 Abstract 13 2  
3 Background and objectives 15   
4 Target population and subgroups 14 1  
5 Setting and location 14 1  
6 Study perspective 15   
7 Comparators 13 2  
8 Time horizon 12 3  
9 Discount rate 5 10  
10 Choice of health outcomes 14 1  
11a Measurement of effectiveness (single study-based estimates) 2 1 12 
11b Measurement of effectiveness (synthesis-based estimates) 6 6 3 
12 Measurement and valuation of preference-based outcomes 5 1 9 
13a Estimating resources and costs (single study-based economic evaluation) 1 2 12 
13b Estimating resources and costs (model-based economic evaluation) 9 3 3 
14 Currency, price date and conversion 12 3  
15 Choice of model 11 1 3 
16 Assumptions 11 1 3 
17 Analytic methods 14 1  
18 Study parameters 9 6  
19 Incremental costs and outcomes 13 2  
20a Characterizing uncertainty (single study-based economic evaluation) 2 1 12 
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20b Characterizing uncertainty (model-based economic evaluation) 9 3 3 
21 Characterizing heterogeneity 6 9  
22 Study findings, limitations, generalizability and current knowledge 11 4  
23 Source of funding 15   
24 Conflicts of interest 12 3  
 626 
  627 
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 628 
Table 3. Proposals for methodological standards for economic evaluations in haemophilia. 629 
1. Compare alternative treatment strategies over time, not individual episodes of care, such 
as the treatment of individual bleeds. 
2. Assess cost-effectiveness over a long time horizon, preferably a lifetime, but also consider 
shorter periods of time if there are uncertainties in the longer term projections. 
3. Base the economic evaluation on a systematic review to obtain estimates of the key 
clinical parameters, and clearly identify the inclusion and exclusion criteria. 
4. If head-to-head clinical studies are not available to estimate relative treatment effect 
and observational data are used, employ an analytic strategy to adequately adjust for 
observed differences, such as differences in study populations and non-observed 
confounders. Crude comparisons of treatment effects in single-arm studies should be 
avoided.  
5. Base drug doses and other treatment patterns on observed data; rely on expert opinion 
or assumptions only as a last resort. 
6. Consider the probable heterogeneity in the patient population and include relevant 
subgroup analyses of cost-effectiveness. 
7. Use a generalizable measure of benefit in the economic study (e.g. for a measure of 
health gain, use QALYs). 
8. Clearly identify all sources of, and values for, unit costs/prices and present these 
separately from the quantities of resources estimated from the treatment patterns. 
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9. Discount future costs and effects at the relevant discount rate for the jurisdiction(s) 
where the economic study is conducted. 
10. Adequately characterize the uncertainty in parameter estimates by using probabilistic 
sensitivity analysis. Additionally, present univariate analyses if these are useful for 
explaining the impact of key structural assumptions. 
11. Consider other factors alongside cost-effectiveness, including patient convenience and 
preferences and the broader impact of the disease and its treatment on families. 
12. Discuss the main weaknesses in the study and explain how and why the results differ 
from other published studies of the treatment strategies being examined. 
 630 
  631 
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Appendix 1 632 
 633 
Search strategy and PRISMA flow diagram 634 
 635 
The following databases were searched, using the search engine ProQuest: MEDLINE 636 
(1946 ?current) and Embase (1947 ?current). The search terms are shown in Table A1.1. 637 
After removal of duplicates, articles were assessed for eligibility according to the 638 
criteria in Table A1.2, in two rounds (first round: inclusion or exclusion based on the 639 
screening of title and abstract only; second round: assessment of full text). Reference 640 
lists of the selected articles and of key review papers were reviewed for potentially 641 
relevant records that might not have been identified by the database search. The 642 
PRISMA flow diagram of the search is shown in Figure A.1. 643 
 644 
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Table A1.1. Search terms for identifying economic evaluations in haemophilia in MEDLINE and 645 
Embase. 646 
Topic # Search term 
Economic evaluation 1 ti,ab( ‘cost effectiveness ? OR  ‘economic evaluation ? OR  ‘cost analysis ? 
OR  ‘cost utility ? OR  ‘cost benefit? ? OR  ‘economic analysis ? OR 
 ‘pharmaco economic? ? OR (economic near model*) OR  ‘decision 
model* ? OR  ‘economic study ? OR  ‘cost-effectiveness ? OR  ‘economic-
evaluation ? OR  ‘cost-analysis ? OR  ‘cost-utility ? OR  ‘cost-benefit? ? OR 
 ‘economic-analysis ? OR  ‘pharmaco-economic? ? OR  ‘decision-model* ? 
OR  ‘economic-study ?) 
Disease 2 ti,ab(hemophilia OR haemophilia OR  ‘Factor VIII Deficiency ? OR 
 ‘Congenital Factor 8 Deficiency ? OR  ‘Factor VIII Deficiency ? OR 
 ‘Congenital Factor VIII Deficiency ?) 
Economic evaluations 
in haemophilia 
3 #1 AND #2 
 647 
 648 
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Table A1.2. Eligibility criteria used in the search for economic evaluations in haemophilia. 649 
Topic Inclusion criteria Exclusion criteria 
Disease Haemophilia, all types Other diseases 
Patient population Adult and paediatric Non-human 
Treatment Treatments, procedures, care 
programmes in haemophilia 
Other 
Economic evaluation Cost-utility, cost-effectiveness, 
cost-minimization studies 
Other 
Document type Journal articles with original 
economic analyses comparing 
treatments, procedures or care 
programmes in haemophilia 
x Conference abstracts 
x Review articles 
x Letters or editorials that 
comment on results of an 
original article 
x Case studies (i.e. a report 
based on only one patient) 
Language English Other language 
Year of publication Published in or after 2008 Published before 2008 
 650 
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 652 
Fig. A.1. PRISMA flow diagram. 653 
 654 
 655 
